DALLAS, Jan. 15, 2010 (GLOBE NEWSWIRE) — BeaconEquity.com announces an investment report featuring medical products maker Osteotech Inc. (Nasdaq:OSTE). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/OSTE
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Osteotech Inc. (OSTE), a medical technology company, develops, processes and distributes biologic products focused on the orthopedic, neurosurgical and oral/maxillofacial surgery markets. The Company is focused on creating technology platforms that provides a variety of procedural specific biologic products to address the changing needs of orthopedics and healthcare in general. The Company’s products focus on biologic solutions for regenerative medicine that can alleviate pain, promote healing and restore functions. OSTE operates in five segments: Demineralized Bone Matrix (DBM), Hybrid/Synthetic, Traditional Tissue, Spinal Allograft, and Human Collagen Technology.
In the report, the analyst notes:
“In its preliminary results for the fourth quarter of 2009, OSTE reported revenue growth of about 7% in the said quarter, citing sales of recently launched bone graft and fusion products. The Company recorded about $400,000 in revenue from its MagniFuse spinal graft products, which reached the market in October, and $200,000 from its FacetLinx fusion system, which was launched in the third quarter.
“For the full year 2009, the Company said it expects $96.7 million in revenue, or $93.4 million excluding the license revenue. It previously expected $92 million to $94 million. OSTE also said it exited 2009 with approximately $10.7 million in cash, above the range of $9 million to $10 million it had expected.”
To read the entire report visit: http://www.beaconequity.com/i/OSTE
See what investors are saying about OSTE at penny stock forum.
BeaconEquity.com is one of the industry’s largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com
